Skip to main content
Caplight Logo









Oxford Cancer Analytics

Oxford Cancer Analytics

Private
OxfordHealthcare & Life Scienceshttps://www.oxcan.org/

Last Round

Series A

Jan 9, 2025

Total Funding Raised

$16.46M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Oxford Cancer Analytics is a healthtech company that develops liquid biopsy blood tests using advanced proteomics and artificial intelligence for the early detection of lung cancer and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Government Contracts, Data as a Service

AI Layer

Application

Keywords

liquid biopsyearly cancer detectioncancer diagnosticsproteomicslung cancer detectionAI diagnosticsprotein biomarkerscancer screeningbiomarker discoveryMedTechprecision medicineminimally invasive testmedical AIclinical trialsdiagnostic labs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oxford Cancer Analytics Comparables

Compare Oxford Cancer Analytics with similar companies based on industry and business-model similarity.

Oxford Cancer Analytics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PrognomiQ
86%
Delfi Diagnostics
85%
Averywell
82%

Oxford Cancer Analytics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 9, 2025
SeedJan 9, 2023
SeedSep 6, 2021

Key People

Founding team and executive leadership

Peter Jianrui Liu

CEO And Co-Founder

Founding Team

Simon Meier

Interim CEO

Executive Team

Oxford Cancer Analytics Investors

Notable investors and investment history

Oxford Cancer Analytics investors
InvestorRounds
OKG CapitalSeries A
We Venture CapitalSeries A
Cancer Research UKSeed
The Francis Crick InstituteSeed
Cross Border Impact VenturesSeries A
DigitalDx VenturesSeries A
LifeArcSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 437% MoM, from 371 to 2K.

  • Jan 9, 2025

    $11M round led by Cross Border Impact Ventures and We Venture Capital.

Oxford Cancer Analytics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oxford Cancer Analytics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oxford Cancer Analytics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range29
Year Founded2021
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?